Aurinia Pharmaceuticals Inc (AUPH) Stock Price

AUPHStock

$16.51+42.94%52W

Market Cap$2.20B

P/E7.65x

PEG Ratio—

Div yield—

Beta1.35

AUPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.17%

Price vs S&P 500 (4W)0.72%

VGM Score70.03

P/E Ratio (Annual)7.65x

P/CF (Annual)16.19x

Book Value / Share (Quarterly)$4.63

P/TBV (Annual)3.64x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)28.31%

Cash Flow / Share (Quarterly)$1.32

Price vs S&P 500 (YTD)-8.42%

Gross Margin (TTM)90.36%

Net Profit Margin (TTM)100.84%

EPS (TTM)$2.29

10-Day Avg Trading Volume0.87M

EPS Excl Extra (TTM)$2.29

Revenue Growth (5Y)41.39%

EPS (Annual)$2.07

ROI (Annual)44.17%

Gross Margin (Annual)88.46%

Net Profit Margin (5Y Avg)-83.64%

Cash / Share (Quarterly)$3.33

P/E Basic Excl Extra (TTM)6.99x

Revenue Growth QoQ (YoY)18.87%

P/E Normalized (Annual)7.65x

ROA (Last FY)38.21%

Revenue Growth TTM (YoY)19.76%

EBITD / Share (TTM)$1.25

ROE (5Y Avg)-6.84%

Operating Margin (TTM)48.39%

Cash Flow / Share (Annual)$1.02

P/B Ratio3.57x

P/B Ratio (Quarterly)3.55x

Net Income / Employee (Annual)$957,300

EV / Revenue (TTM)6.67x

Net Interest Coverage (TTM)-7.31x

ROA (TTM)44.95%

EPS Growth QoQ (YoY)79.16%

EV / EBITDA (TTM)12.21x

EPS Incl Extra (Annual)$2.07

Current Ratio (Annual)5.25x

Quick Ratio (Quarterly)4.86x

3-Month Avg Trading Volume1.22M

52-Week Price Return42.94%

EV / Free Cash Flow (Annual)15.34x

P/E Incl Extra (TTM)6.99x

Revenue / Employee (TTM)$1,038,400

Tangible BV / Share (Quarterly)$4.60

P/S Ratio (Annual)7.76x

Asset Turnover (Annual)0.38x

52-Week High$19.25

Operating Margin (5Y Avg)-99.33%

EPS Excl Extra (Annual)$2.07

CapEx CAGR (5Y)-49.05%

Tangible BV CAGR (5Y)7.70%

26-Week Price Return2.74%

Quick Ratio (Annual)4.70x

13-Week Price Return3.45%

Total Debt / Equity (Annual)0.12x

Current Ratio (Quarterly)5.42x

Enterprise Value$2.08B

Revenue / Share Growth (5Y)37.00%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)6.42%

Revenue / Employee (Annual)$943,500

Inventory Turnover (Annual)0.77x

Pretax Margin (Annual)40.33%

Cash / Share (Annual)$3.01

3-Month Return Std Dev33.04%

Gross Margin (5Y Avg)92.36%

Net Income / Employee (TTM)$1,047,000

ROE (Last FY)49.40%

Net Interest Coverage (Annual)-0.61x

EPS Basic Excl Extra (Annual)$2.07

P/FCF (TTM)12.55x

Receivables Turnover (TTM)7.67x

EV / Free Cash Flow (TTM)11.87x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$2.29

Receivables Turnover (Annual)7.26x

ROI (TTM)52.45%

P/S Ratio (TTM)7.05x

Pretax Margin (5Y Avg)-95.04%

Revenue / Share (Annual)$2.04

Tangible BV / Share (Annual)$4.36

Forward P/E15.12x

Price vs S&P 500 (52W)27.41%

P/E Ratio (TTM)6.99x

EPS Growth TTM (YoY)435.82%

Year-to-Date Return3.51%

5-Day Price Return-0.24%

EPS Normalized (Annual)$2.07

ROA (5Y Avg)-6.26%

Net Profit Margin (Annual)101.47%

Month-to-Date Return1.95%

Cash Flow / Share (TTM)$-0.49

EBITD / Share (Annual)$0.90

Operating Margin (Annual)37.06%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)12.54x

ROI (5Y Avg)-7.14%

P/E Excl Extra (TTM)6.99x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$2.29

P/TBV (Quarterly)3.57x

P/B Ratio (Annual)3.62x

Inventory Turnover (TTM)0.66x

Pretax Margin (TTM)51.48%

Book Value / Share (Annual)$4.39

Price vs S&P 500 (13W)0.76%

Beta1.35x

P/FCF (Annual)16.22x

Revenue / Share (TTM)$2.33

ROE (TTM)59.00%

52-Week Low$11.30

vGradeC

gGradeB

mGradeB

vgmGradeB

AUPH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.24	$0.28	+16.67%(+$0.04)
Q1 2026	May 7, 2026	$0.20	$0.25	+26.58%(+$0.05)
Q4 2025	Feb 26, 2026	$0.22	$1.53	+606.14%(+$1.31)
Q3 2025	Nov 4, 2025	$0.16	$0.23	+43.75%(+$0.07)
Q2 2025	Jul 31, 2025	$0.15	$0.16	+9.09%(+$0.01)

AUPH Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.92

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AUPHAurinia Pharmaceuticals Inc	C	B	B	7.1x	19.8%	90.4%	—	$16.51
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is a biopharmaceutical company specializing in autoimmune diseases with significant unmet medical needs. The company commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral therapy for active lupus nephritis in adult patients, and is developing aritinercept, a dual BAFF/APRIL inhibitor for additional autoimmune indications.

AUPH Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.22

Revenue estimate$83.15M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AUPH Insider Transactions

SellSep 10, 2026
ROBERTSON STEPHEN P
Officer
Shares: 11,939Value: $190,427
SellAug 21, 2026
ROBERTSON STEPHEN P
Officer
Shares: 20,975Value: $355,946

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$11.30

High$19.25